Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses
Por:
Rocha-Zavaleta L., Alejandre J.E., Garcia-Carranca A.
Publicada:
1 ene 2002
Resumen:
The association of human papillomavirus (HPV) infection and cervical cancer has been demonstrated. The development of a prophylactic vaccine to protect against primary HPV infection may therefore be an efficient means to reduce the incidence of this cancer worldwide. To assess the capacity of a plasmid DNA that expresses the L1 gene of HPV type 16 to induce a protective iramune response, mice were immunized by parenteral and oral routes. Animals that received the DNA vaccine intramuscularly, subcutaneously and orally, developed systemic anti-L1 lgG antibodies. Antibodies developed in mice vaccinated subcutaneously were detectable twelve months post-immunization. Specific lgA antibodies were also found in vaginal washes from immunized mice. Both systemic and local antibodies proved effective in a surrogate neutralization assay. Splenic T cells extracted from experimental mice showed cytotoxic T lymphocytes (CTL) activity mediated by CD8+ cells. Mice were challenged with a syngeneic melanoma cell line, engineered to express the HPV16-L1 protein, tumours in vaccinated animals showed slower growth rate, correlated directly with a longer survival of mice. The results suggest that the L1-based DNA vaccine may be useful for the prevention of primary infections by HPV16. © 2002 Wiley-Liss, Inc.
Filiaciones:
Rocha-Zavaleta L.:
Department of Molecular Biology, Institute of Biomedical Research, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico
Alejandre J.E.:
Department of Molecular Biology, Institute of Biomedical Research, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico
Garcia-Carranca A.:
Research Division, National Cancerology Institute, Mexico City, Mexico
|